Karasik, A, Lanzinger, S, Chia-Hui Tan, E, Yabe, D, Kim, D J, Sheu, W H H, Melzer-Cohen, C, Holl, R W, Ha, K H, Khunti, K, Zaccardi, F, Subramanian, A, Nirantharakumar, K, Nyström, T, Niskanen, L, Linnemann Jensen, M, Hoti, F, Klement, R, Déruaz-Luyet, A, Kyaw, M H, Koeneman, L, Vistisen, D, Carstensen, B, Halvorsen, S, Langslet, G, Fazeli Farsani, S, Patorno, E, Núñez, J & EMPRISE Europe and Asia Study Group 2023, ' Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia : Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study ', Diabetes and Metabolism, vol. 49, no. 2, 101418 . https://doi.org/10.1016/j.diabet.2022.101418
Kohsaka, S, Lam, C S P, Kim, D J, Cavender, M A, Norhammar, A, Jørgensen, M E, Birkeland, K, Holl, R W, Franch-Nadal, J, Tangri, N, Shaw, J, Ilomäki, J, Karasik, A, Goh, S Y, Chiang, C E, Thuresson, M, Chen, H, Wittbrodt, E, Bodegård, J, Surmont, F, Fenici, P & Kosiborod, M 2020, ' Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors : an analysis from the CVD-REAL 2 multinational cohort study ', The Lancet Diabetes and Endocrinology, vol. 8, no. 7, pp. 606-615 . https://doi.org/10.1016/S2213-8587(20)30130-3 Lancet Diabetes & Endocrinology, 8(7), 606-615. ELSEVIER SCIENCE INC